Abstract 491P
Background
Furmonertinib (AST2818) is a novel, promising oral third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR sensitive mutations and T790M mutation, which has demonstrated efficacy in NSCLC in previous clinical trials. However, the efficacy and safety of furmonertinib as adjuvant therapy in patients ≥ 65 years old remain unclear.
Methods
Patients who underwent radical lung cancer surgery with EGFR mutations from two independent medical centers were enrolled and received furmonertinib 80mg daily. The adjuvant therapy time (6-36months) depended on patients’pathologic stage and physical conditions. The disease-free survival (DFS), safety and tolerability were evaluated.
Results
This study retrospectively analyzed 101 patients who were pathologically confirmed adenocarcinoma, EGFR mutation-positive (exon 19 deletion/L858R), stage IA2-IIIA NSCLC (60 females, 41 males, ranging in age from 43 to 86 years, with a median age of 65). Among them, 55 cases were ≥ 65 years old (median age 69 years, including 21 ≥ 70 years old), and 46 cases were<65 years old (median age 56.5 years old). All patients were followed at least 10 months, and 68 (67.3%) of them have been followed up for over 2 years, median follow-up time was 22 months. At data cutoff, all patients were alive, only 3 of them had metastasis (CNS, chest wall, and pancreas, respectively). The 2-year DFS rates for patients ≥ 65 years old and<65 years old were 96% and 97%, respectively (p=0.98). During therapy, 39 (38.6%) patients had treatment-related adverse events (TRAEs) of any grade. The most common TRAEs were rash (19/101, 18.8%), mouth ulcer (9/101, 8.9%) ,diarrhea (9/101, 8.9%) and transaminase elevation (5/101, 5.0%). Only 3 (3.0%) patients had TRAEs of grade 3 or higher and 1(1.4%) of them discontinued therapy. There was no significant difference in the incidence of TRAEs of any grade in patients aged ≥ 65 years and < 65 years (30.9% and 47.8%, p=0.08, respectively).
Conclusions
This is the first real-world study to demonstrate that furmonertinib has good efficacy and a tolerable safety profile in elderly patients (≥ 65 years) with completely resected stage I-III NSCLC harboring EGFR mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract